Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Olympus(ALIOF)Astellas PharmaBeiGeneTerumo
SymbolOTCMKTS:OCPNYOTCMKTS:ALIOFOTCMKTS:ALPMYNASDAQ:BGNEOTCMKTS:TRUMY
Price Information
Current Price$21.44$278.50$15.14$305.54$38.11
52 Week RangeStrong BuyN/ABuyHoldHold
MarketRank™
Overall Score1.20.41.71.30.8
Analysis Score0.00.00.02.20.0
Community Score2.42.12.72.82.3
Dividend Score1.70.02.50.00.8
Ownership Score0.00.00.00.80.0
Earnings & Valuation Score1.90.03.10.60.6
Analyst Ratings
Consensus RecommendationStrong BuyN/ABuyHoldHold
Consensus Price TargetN/AN/AN/A$319.38N/A
% Upside from Price TargetN/AN/AN/A4.53% upsideN/A
Trade Information
Market Cap$29.39 billion$29.89 billion$28.19 billion$28.02 billion$28.95 billion
Beta0.680.210.630.910.38
Average Volume35,63592474,837309,02134,823
Sales & Book Value
Annual Revenue$7.32 billionN/A$11.97 billion$428.21 million$5.79 billion
Price / Sales4.01N/A2.3665.435.00
Cashflow$0.86 per shareN/A$1.21 per shareN/A$1.55 per share
Price / Cash24.80N/A12.47N/A24.60
Book Value$2.51 per shareN/A$6.28 per share$15.87 per share$9.14 per share
Price / Book8.54N/A2.4119.254.17
Profitability
Net Income$475.36 millionN/A$1.80 billion$-948,630,000.00$783.93 million
EPS$0.36N/A$0.96($15.80)$1.04
Trailing P/E Ratio76.570.0021.94N/A37.00
Forward P/E Ratio35.159.96N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins5.34%N/A11.03%-569.22%12.58%
Return on Equity (ROE)10.82%N/A13.24%-56.81%10.24%
Return on Assets (ROA)3.98%N/A7.89%-39.93%6.29%
Dividend
Annual Payout$0.07N/A$0.29N/A$0.19
Dividend Yield0.33%N/A1.92%N/A0.50%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout Ratio19.44%N/A30.21%N/A18.27%
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.02%N/AN/A0.04%0.32%
Current Ratio1.88%N/A1.23%7.69%2.60%
Quick Ratio1.35%N/A0.99%7.64%1.75%
Ownership Information
Institutional Ownership Percentage0.10%N/A0.18%60.65%0.02%
Insider Ownership PercentageN/AN/AN/A9.00%N/A
Miscellaneous
Employees35,174N/A15,8835,30026,438
Shares Outstanding1.37 billion107.33 million1.86 billion91.70 million759.52 million
Next Earnings Date6/4/2021 (Estimated)N/A5/13/2021 (Estimated)5/10/2021 (Estimated)5/17/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Terumo is building a Global Therapeutic Interventional Oncology team to offer more therapeutic solution to cancer patientsTerumo is building a Global Therapeutic Interventional Oncology team to offer more therapeutic solution to cancer patients
finance.yahoo.com - April 12 at 1:13 PM
Terumo Co. (OTCMKTS:TRUMY) Short Interest UpdateTerumo Co. (OTCMKTS:TRUMY) Short Interest Update
americanbankingnews.com - March 28 at 9:10 AM
Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.
finance.yahoo.com - February 23 at 6:56 PM
Lower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA ApprovalLower-Profile Web Intrasaccular Aneurysm Treatment Device Receives FDA Approval
finance.yahoo.com - January 12 at 10:54 AM
IceCure Inks Expanded Distribution Agreement with Terumo Corporation for ThailandIceCure Inks Expanded Distribution Agreement with Terumo Corporation for Thailand
markets.businessinsider.com - January 5 at 8:43 AM
Terumo Enters 100th Anniversary YearTerumo Enters 100th Anniversary Year
finance.yahoo.com - January 5 at 8:43 AM
MicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLCMicroVention, Inc. Files Trade Secret Lawsuit Against Balt USA, LLC
finance.yahoo.com - December 23 at 11:30 AM
Terumo PE Ratio:Terumo PE Ratio:
ycharts.com - December 9 at 11:22 PM
IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 MillionIceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
prnewswire.com - October 5 at 12:47 PM
Terumo extends strategic collaboration with IceCure MedicalTerumo extends strategic collaboration with IceCure Medical
seekingalpha.com - October 5 at 12:47 PM
India ECB, FCCB and RDB data for August 2020India ECB, FCCB and RDB data for August 2020
in.reuters.com - October 5 at 7:46 AM
MicroVention-Terumo Announces New LeadershipMicroVention-Terumo Announces New Leadership
finance.yahoo.com - September 22 at 10:56 AM
Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19
finance.yahoo.com - August 24 at 8:58 AM
Neurointerventional Devices Market To Witness the Highest Growth Globally in Coming Years 2020-2025Neurointerventional Devices Market To Witness the Highest Growth Globally in Coming Years 2020-2025
www.marketwatch.com - July 22 at 8:08 AM
Terumo completes acquisition of Quirem Medical, acquires 80.1% of sharesTerumo completes acquisition of Quirem Medical, acquires 80.1% of shares
seekingalpha.com - July 15 at 5:30 AM
Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology FieldTerumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field
finance.yahoo.com - July 15 at 5:30 AM
UV light robot destroys coronavirus in 2 minutesUV light robot destroys coronavirus in 2 minutes
finance.yahoo.com - May 12 at 10:11 PM
Vascular Graft Market 2020 In Deep Analysis, Expert Reviews and Healthcare Outlook 2025Vascular Graft Market 2020 In Deep Analysis, Expert Reviews and Healthcare Outlook 2025
www.openpr.com - May 7 at 3:54 PM
IceCure Continues Global Expansion to Freeze TumorsIceCure Continues Global Expansion to Freeze Tumors
www.prnewswire.com - April 20 at 8:40 AM
Terumo, Marker Therapeutics win emergency nod for blood-treatment systemTerumo, Marker Therapeutics win emergency nod for blood-treatment system
www.massdevice.com - April 10 at 12:35 PM
FDA grants emergency authorization to two blood purification systemsFDA grants emergency authorization to two blood purification systems
finance.yahoo.com - April 10 at 12:35 PM
Coronavirus update: 1.62 million cases worldwide, 97,200 deaths, and U.S. fatalities are second only to ItalyCoronavirus update: 1.62 million cases worldwide, 97,200 deaths, and U.S. fatalities are second only to Italy
finance.yahoo.com - April 10 at 12:35 PM
Terumo Corporation (TRUMY)Terumo Corporation (TRUMY)
finance.yahoo.com - March 26 at 11:24 PM
Disposable Clothing Market 2020 Demand Analysis and Growth Outlook - Baxter International Inc.(nys:BAX), Terumo Corp.TRUMF, Halyard HealthDisposable Clothing Market 2020 Demand Analysis and Growth Outlook - Baxter International Inc.(nys:BAX), Terumo Corp.TRUMF, Halyard Health
www.marketwatch.com - February 11 at 7:51 AM
MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain AneurysmsMicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms
finance.yahoo.com - January 9 at 3:48 PM
DateCompanyBrokerageAction
1/11/2021OlympusThe Goldman Sachs GroupInitiated Coverage
1/23/2020Astellas PharmaMorgan StanleyInitiated Coverage
9/24/2019Astellas PharmaJefferies Financial GroupInitiated Coverage
11/5/2018Astellas PharmaJPMorgan Chase & Co.Downgrade
9/13/2018Astellas PharmaDeutsche Bank AktiengesellschaftDowngrade
3/16/2021BeiGeneHSBCBoost Price Target
3/8/2021BeiGeneChina Renaissance SecuritiesInitiated Coverage
3/1/2021BeiGeneCLSADowngrade
2/25/2021BeiGeneCowenBoost Price Target
1/12/2021BeiGenePiper SandlerBoost Price Target
12/8/2020BeiGeneLADENBURG THALM/SH SHUpgrade
11/19/2020BeiGeneSVB LeerinkBoost Price Target
11/6/2020BeiGeneMaxim GroupDowngrade
3/13/2020BeiGeneMacquarieUpgrade
1/14/2021TerumoCredit Suisse GroupDowngrade
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.